The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma

Summary

This is a single arm clinical study to estimate the safety, tolerability and pharmacokinetic (PK) characteristics of Chimeric Antigen Receptor-modified T cells (CAR-T) SNC-109 in patients with recurrent glioblastoma (r-GBM) and preliminarily evaluate the effectiveness, the immunogenicity of the product, as well as their correlation between the changes of cytokines from baseline level after cellular infusion.

Timeline

Start

2022-06-24

Primary completion

2024-05

Completion

2024-08

Drugs

Indications